Literature DB >> 9798607

Malignant hyperthermia.

M Denborough1.   

Abstract

A specific inherited muscle membrane disorder predisposes to a variety of clinical problems. The most common is malignant hyperthermia (MH), a dangerous hypermetabolic state after anaesthesia with suxamethonium and/or volatile halogenated anaesthetic agents. MH may also be triggered in susceptible individuals by severe exercise in hot conditions, infections, neuroleptic drugs, and overheating in infants. Inbred pigs have provided a helpful model, and experiments on these animals and in MH-susceptible patients have shown that the essential biochemical abnormality is an increase in calcium ions in the muscle cells. This knowledge has led to a specific muscle test to identify susceptibility to MH and to a specific treatment, dantrolene; and as a result the case-fatality rate in MH has fallen from 70% in the 1970s to 5% today. In pigs susceptibility to MH is caused by a single mutation in the ryanodine receptor (RYR) in skeletal muscle. In man the genetics is more complex and three clinical myopathies that predispose to MH have been defined. By far the most common is inherited as a mendelian dominant characteristic and at present mutations in the human RYR account for no more than 20% of susceptible families.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9798607     DOI: 10.1016/S0140-6736(98)03078-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  49 in total

1.  Some light from the heat: implications of rave parties for clinicians.

Authors:  M J Rieder
Journal:  CMAJ       Date:  2000-06-27       Impact factor: 8.262

2.  Statin-induced muscle toxicity and susceptibility to malignant hyperthermia and other muscle diseases: a population-based case-control study including 1st and 2nd degree relatives.

Authors:  Karin Hedenmalm; Arzu Gunes Granberg; Marja-Liisa Dahl
Journal:  Eur J Clin Pharmacol       Date:  2014-11-01       Impact factor: 2.953

3.  Potent Inhalational Anesthetics for Dentistry.

Authors:  Mary Satuito; James Tom
Journal:  Anesth Prog       Date:  2016

4.  Functional properties of ryanodine receptors carrying three amino acid substitutions identified in patients affected by multi-minicore disease and central core disease, expressed in immortalized lymphocytes.

Authors:  Sylvie Ducreux; Francesco Zorzato; Ana Ferreiro; Heinz Jungbluth; Francesco Muntoni; Nicole Monnier; Clemens R Müller; Susan Treves
Journal:  Biochem J       Date:  2006-04-15       Impact factor: 3.857

Review 5.  Stressed out: the skeletal muscle ryanodine receptor as a target of stress.

Authors:  Andrew M Bellinger; Marco Mongillo; Andrew R Marks
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

Review 6.  Endoplasmic reticulum Ca(2+) handling in excitable cells in health and disease.

Authors:  Grace E Stutzmann; Mark P Mattson
Journal:  Pharmacol Rev       Date:  2011-07-07       Impact factor: 25.468

7.  Anesthetic- and heat-induced sudden death in calsequestrin-1-knockout mice.

Authors:  Marco Dainese; Marco Quarta; Alla D Lyfenko; Cecilia Paolini; Marta Canato; Carlo Reggiani; Robert T Dirksen; Feliciano Protasi
Journal:  FASEB J       Date:  2009-02-23       Impact factor: 5.191

8.  Anesthetic-induced neurodegeneration mediated via inositol 1,4,5-trisphosphate receptors.

Authors:  Yifan Zhao; Ge Liang; Qianru Chen; Donald J Joseph; Qingcheng Meng; Roderic G Eckenhoff; Maryellen F Eckenhoff; Huafeng Wei
Journal:  J Pharmacol Exp Ther       Date:  2010-01-19       Impact factor: 4.030

9.  [Onset of a fulminant malignant hyperthermia crisis. Case report of a 74-year-old patient with previously subclinical central core disease].

Authors:  M Wejbora; H Bornemann-Cimenti; D Lessel; C Mandl; H Voit-Augustin; G Schwarz
Journal:  Anaesthesist       Date:  2012-12-19       Impact factor: 1.041

10.  A double mutation of the ryanodine receptor type 1 gene in a malignant hyperthermia family with multiminicore myopathy.

Authors:  Seul-Ki Jeong; Dong-Chan Kim; Yong-Gon Cho; Il-Nam Sunwoo; Dal-Sik Kim
Journal:  J Clin Neurol       Date:  2008-09-30       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.